Asset Management One Co. Ltd. increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,524,956 shares of the company’s stock after purchasing an additional 95,627 shares during the quarter. Johnson & Johnson comprises about 1.4% of Asset Management One Co. Ltd.’s holdings, making the stock its 6th largest position. Asset Management One Co. Ltd. owned 0.17% of Johnson & Johnson worth $588,092,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. AMP Capital Investors Ltd grew its position in Johnson & Johnson by 1.5% during the third quarter. AMP Capital Investors Ltd now owns 1,169,787 shares of the company’s stock worth $152,084,000 after buying an additional 17,352 shares in the last quarter. Advantage Investment Management LLC grew its position in Johnson & Johnson by 4.3% during the third quarter. Advantage Investment Management LLC now owns 14,944 shares of the company’s stock worth $1,943,000 after buying an additional 611 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its position in Johnson & Johnson by 16.1% during the third quarter. Nomura Asset Management Co. Ltd. now owns 968,195 shares of the company’s stock worth $125,875,000 after buying an additional 134,575 shares in the last quarter. Lido Advisors LLC grew its position in Johnson & Johnson by 27.3% during the third quarter. Lido Advisors LLC now owns 14,727 shares of the company’s stock worth $2,053,000 after buying an additional 3,159 shares in the last quarter. Finally, B. Riley Financial Inc. purchased a new position in Johnson & Johnson during the third quarter worth about $716,000. Institutional investors own 67.35% of the company’s stock.
In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. During the same quarter in the previous year, the company posted $1.58 EPS. Johnson & Johnson’s revenue for the quarter was up 11.5% on a year-over-year basis. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.88%.
Several research firms recently commented on JNJ. JPMorgan Chase & Co. cut Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 target price for the company in a research report on Wednesday, December 20th. BMO Capital Markets boosted their target price on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, February 26th. Finally, BTIG Research restated a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $146.26.
ILLEGAL ACTIVITY NOTICE: “Asset Management One Co. Ltd. Has $588.09 Million Stake in Johnson & Johnson (JNJ)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/asset-management-one-co-ltd-has-588-09-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.